GSK CEO Emma Walmsley with Endpoints' Drew Armstrong at the Financial Times' Global Pharma and Biotech Summit (courtesy Financial Times)

November 6, 2024 01:49 PM EST

China

Pharma

GSK CEO Emma Walmsley on the new Trump administration, trust, AI and China

Drew Armstrong

Executive Editor

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley believes her company can …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK CEO Emma Walmsley on the new Trump administration, trust, AI and China

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Biotech industry worries over potential for RFK Jr. ally as FDA pick

New Trump era could be a boon for biopharma M&A, dealmaking

California voters say yes to restrictions around 340B spending

‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugs

At this year's ObesityWeek, GLP-1s aren’t the only talk of the town

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

Executive Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

GSK CEO Emma Walmsley on the new Trump administration, trust, AI and China